Alexandria Real Estate Equities Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Class Action Deadline: The lead plaintiff deadline for the Alexandria Real Estate securities class action is January 26, 2026, requiring investors to apply by this date to represent other investors and protect their rights.
- Potential Compensation: Investors who purchased Alexandria Real Estate securities between January 27, 2025, and October 27, 2025, may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, reducing their financial burden.
- False Information Disclosure: The lawsuit alleges that defendants provided investors with positive information regarding Alexandria Real Estate's expected revenue and funds from operations while concealing significant adverse facts about its Long Island City property, leading to investor losses when the truth emerged.
- Law Firm Advantage: The Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities and successful track record in this field.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 51.53 USD with a low forecast of 15.84 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
11 Hold
0 Sell
Moderate Buy
Current: 57.260
Low
15.84
Averages
51.53
High
67.00
Current: 57.260
Low
15.84
Averages
51.53
High
67.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
